A skin cancer vaccination called IFx-Hu2.0 received FDA “fast track” designation to treat patients with advanced cutaneous melanoma who have not responded to other therapies and medication.
The FDA Oncologic Drugs Advisory Committee on Sept. 26 voted that PD-L1 inhibitors should not be indicated as a first-line treatment for patients with PD-L1-negative gastric/gastroesophageal junction adenocarcinoma and esophageal squamous cell carcinoma.
